NICHD P1081: Improved Virologic Suppression at Delivery With RAL- vs EFV-Based ART in Pregnant Women With HIV Infection

March 4-7, 2019; Seattle, Washington
First large randomized study of raltegravir vs efavirenz in pregnant women finds improved virologic suppression at delivery in women receiving raltegravir, particularly when initiating ART after 28 weeks of gestation.
Format: Microsoft PowerPoint (.ppt)
File Size: 181 KB
Released: March 7, 2019

Acknowledgements

Directly provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This program is supported by independent educational grants from
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Related Content

Michelle Sherman, RPh, FASCP, FACA, AAHIVP, discusses how pharmacists can improve HIV care outcomes through testing, prevention, and MTM services

Michelle J. Sherman, RPh, APh, FASCP, FACA, AAHIVP Released: August 20, 2019

Downloadable audio from Jürgen K. Rockstroh, MD, with analysis of key new HIV data from IAS 2019 on NTD risk in pregnancy, PrEP, and emerging ART options

Jürgen K. Rockstroh, MD Released: August 20, 2019

Jürgen K. Rockstroh, MD, on IAS 2019 data reporting phase III safety and efficacy of dual therapy with dolutegravir plus lamivudine (GEMINI and TANGO)

Jürgen K. Rockstroh, MD Released: August 20, 2019

Watch this CME/CE-certified video for guidance from Monica Gandhi, MD, MPH, and Jason Halperin, MD, MPH, on implementing rapid ART initiation.

Monica Gandhi, MD, MPH Jason Halperin, MD, MPH Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: August 19, 2019 Expiration: August 18, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?